3.62
price down icon2.43%   -0.09
after-market アフターアワーズ: 3.60 -0.02 -0.55%
loading
前日終値:
$3.71
開ける:
$3.68
24時間の取引高:
456.42K
Relative Volume:
0.73
時価総額:
$167.71M
収益:
$20.72M
当期純損益:
$-100.84M
株価収益率:
-1.3609
EPS:
-2.66
ネットキャッシュフロー:
$-78.56M
1週間 パフォーマンス:
+3.72%
1か月 パフォーマンス:
+11.73%
6か月 パフォーマンス:
-53.83%
1年 パフォーマンス:
-85.31%
1日の値動き範囲:
Value
$3.48
$3.72
1週間の範囲:
Value
$3.365
$3.805
52週間の値動き範囲:
Value
$2.235
$28.93

4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Name
名前
4 D Molecular Therapeutics Inc
Name
セクター
Healthcare (1170)
Name
電話
(510) 505-2680
Name
住所
5858 HORTON STREET #455, EMERYVILLE
Name
職員
227
Name
Twitter
Name
次回の収益日
2024-12-13
Name
最新のSEC提出書
Name
FDMT's Discussions on Twitter

FDMT を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
FDMT
4 D Molecular Therapeutics Inc
3.62 161.67M 20.72M -100.84M -78.56M -2.66
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-01-13 ダウングレード BMO Capital Markets Outperform → Market Perform
2024-11-21 開始されました Morgan Stanley Underweight
2024-09-23 ダウングレード Cantor Fitzgerald Overweight → Neutral
2024-04-15 開始されました Barclays Overweight
2024-02-07 再開されました Goldman Buy
2023-10-26 開始されました RBC Capital Mkts Outperform
2023-10-24 開始されました Cantor Fitzgerald Overweight
2023-10-18 アップグレード Leerink Partners Market Perform → Outperform
2023-07-05 開始されました Chardan Capital Markets Buy
2023-01-30 開始されました BMO Capital Markets Outperform
2022-11-18 開始されました H.C. Wainwright Buy
2022-11-15 アップグレード Goldman Neutral → Buy
2022-08-12 ダウングレード SVB Leerink Outperform → Mkt Perform
2022-06-22 開始されました Jefferies Buy
2022-01-04 開始されました SVB Leerink Outperform
2021-01-05 開始されました BofA Securities Buy
2021-01-05 開始されました Evercore ISI Outperform
2021-01-05 開始されました Goldman Neutral
すべてを表示

4 D Molecular Therapeutics Inc (FDMT) 最新ニュース

pulisher
May 31, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World

May 31, 2025
pulisher
May 29, 2025

D. E. Shaw & Co. Inc. Grows Stake in Nektar Therapeutics (NASDAQ:NKTR) - Defense World

May 29, 2025
pulisher
May 29, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Position Lowered by D. E. Shaw & Co. Inc. - Defense World

May 29, 2025
pulisher
May 28, 2025

4DMT to Participate in Upcoming Investor Conferences | FDMT Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

4DMT to Participate in Upcoming Investor Conferences - Eagle-Tribune

May 28, 2025
pulisher
May 28, 2025

4DMT Leadership to Present Latest Biotech Advances at Two Major Healthcare Conferences in June - Stock Titan

May 28, 2025
pulisher
May 27, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Receives Sell (E+) Rating from Weiss Ratings - Defense World

May 27, 2025
pulisher
May 27, 2025

Millennium Management LLC Acquires 1,337,497 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

May 27, 2025
pulisher
May 26, 2025

4D Molecular Therapeutics’ SWOT analysis: gene therapy stock faces durability challenges amid pipeline progress - Investing.com

May 26, 2025
pulisher
May 25, 2025

Deutsche Bank AG Sells 560,784 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

May 25, 2025
pulisher
May 25, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Acquired by Northern Trust Corp - Defense World

May 25, 2025
pulisher
May 25, 2025

BNP Paribas Financial Markets Makes New Investment in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

May 25, 2025
pulisher
May 21, 2025

Spotlight On 3 Penny Stocks With Market Caps Under $500M - Yahoo Finance

May 21, 2025
pulisher
May 21, 2025

Jane Street Group LLC Increases Stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

May 21, 2025
pulisher
May 18, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by Price T Rowe Associates Inc. MD - Defense World

May 18, 2025
pulisher
May 17, 2025

Dimensional Fund Advisors LP Cuts Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

May 17, 2025
pulisher
May 16, 2025

4DMT Boosts Talent Acquisition: 31,800 RSUs Granted as Biotech Firm Accelerates Growth - Stock Titan

May 16, 2025
pulisher
May 15, 2025

FY2025 EPS Estimates for FDMT Decreased by Cantor Fitzgerald - Defense World

May 15, 2025
pulisher
May 15, 2025

HC Wainwright Analysts Boost Earnings Estimates for FDMT - Defense World

May 15, 2025
pulisher
May 12, 2025

Chardan Adjusts Price Target on 4D Molecular Therapeutics to $25 From $28, Maintains Buy Rating - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

Hsbc Holdings PLC Grows Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

May 12, 2025
pulisher
May 12, 2025

Barclays Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $38.00 - Defense World

May 12, 2025
pulisher
May 12, 2025

The Goldman Sachs Group Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $44.00 - Defense World

May 12, 2025
pulisher
May 12, 2025

Chardan Capital Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $25.00 - Defense World

May 12, 2025
pulisher
May 11, 2025

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates - MSN

May 11, 2025
pulisher
May 11, 2025

Wells Fargo & Company MN Boosts Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

May 11, 2025
pulisher
May 11, 2025

Contrasting Genfit (NASDAQ:GNFT) & 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World

May 11, 2025
pulisher
May 11, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (E+)” Rating at Weiss Ratings - Defense World

May 11, 2025
pulisher
May 09, 2025

Barclays Adjusts Price Target for 4D Molecular (FDMT) | FDMT Sto - GuruFocus

May 09, 2025
pulisher
May 09, 2025

RBC Cuts Price Target on 4D Molecular Therapeutics to $26 From $35, Keeps Outperform, Speculative Risk - marketscreener.com

May 09, 2025
pulisher
May 09, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by Barclays PLC - The AM Reporter

May 09, 2025
pulisher
May 09, 2025

Barclays Adjusts Price Target for 4D Molecular (FDMT) | FDMT Stock News - GuruFocus

May 09, 2025
pulisher
May 09, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $26.71 Consensus Price Target from Brokerages - Defense World

May 09, 2025
pulisher
May 09, 2025

4D Molecular Therapeutics Reports Increased Quarterly Loss - TipRanks

May 09, 2025
pulisher
May 08, 2025

4D Molecular Therapeutics Inc Reports Q1 2025 EPS of -$0.86, Missing Estimates; Revenue Falls Short at $14,000 - GuruFocus

May 08, 2025
pulisher
May 08, 2025

4D Molecular Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 08, 2025
pulisher
May 08, 2025

4D Molecular Therapeutics, Inc. SEC 10-Q Report - TradingView

May 08, 2025
pulisher
May 08, 2025

4D Molecular Therapeutics Enrolls First Patients in Phase 3 Clinical Trials for 4D-150 in Wet AMD, Receives FDA RMAT Designation for DME - Nasdaq

May 08, 2025
pulisher
May 08, 2025

4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones - GlobeNewswire

May 08, 2025
pulisher
May 08, 2025

FDMT4D Molecular Therapeutics Inc. Latest Stock News & Market Updates - Stock Titan

May 08, 2025
pulisher
May 08, 2025

Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Raymond James Financial Inc. Invests $629,000 in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

May 08, 2025
pulisher
May 07, 2025

Gene Therapy in Ophthalmology Industry Report 2025-2035: Global Market Poised for Growth as Inherited Retinal Disease Cases Surge Worldwide - GlobeNewswire Inc.

May 07, 2025
pulisher
May 07, 2025

Financial Comparison: 4D Molecular Therapeutics (NASDAQ:FDMT) and Cardiff Oncology (NASDAQ:CRDF) - Defense World

May 07, 2025
pulisher
May 05, 2025

4D Molecular Therapeutics Inc expected to post a loss of 86 cents a shareEarnings Preview - TradingView

May 05, 2025
pulisher
May 02, 2025

Are 4D Molecular Therapeutics Inc’shares a good deal? - uspostnews.com

May 02, 2025
pulisher
May 01, 2025

Synhale Therapeutics Acquires Telaglenastat, Accelerates Development for Pulmonary Hypertension Treatment - The Malaysian Reserve

May 01, 2025
pulisher
May 01, 2025

4D Molecular's Macular Edema Treatment Gets Regenerative Medicine Designation from FDA - marketscreener.com

May 01, 2025
pulisher
May 01, 2025

4D Molecular Therapeutics' 4D-150 Receives RMAT Designation For Diabetic Macular Edema - Nasdaq

May 01, 2025
pulisher
May 01, 2025

4D Molecular wins RMAT status for eye therapy (FDMT:NASDAQ) - Seeking Alpha

May 01, 2025
pulisher
May 01, 2025

4D Molecular Therapeutics receives RMAT designation for 4D-150 for the treatment of diabetic macular edema - Ophthalmology Times

May 01, 2025

4 D Molecular Therapeutics Inc (FDMT) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
大文字化:     |  ボリューム (24 時間):